158 related articles for article (PubMed ID: 36907571)
1. The prime time for management of hepatocellular carcinoma in Hong Kong.
Chan LL; Chan SL
Clin Mol Hepatol; 2023 Apr; 29(2):345-348. PubMed ID: 36907571
[No Abstract] [Full Text] [Related]
2. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
Sacco R; Antonucci M; Bargellini I; Marceglia S; Mismas V; Cabibbo G
Future Oncol; 2015; 11(17):2371-3. PubMed ID: 26270206
[No Abstract] [Full Text] [Related]
3. Is lenvatinib in combination with transarterial chemoembolization benefit for unresectable hepatocellular carcinoma (uHCC)? The age interference needs to be eliminated.
Li S; Li Y
Hepatol Int; 2024 Apr; 18(2):704-705. PubMed ID: 37943415
[No Abstract] [Full Text] [Related]
4. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Geschwind JF; Chapiro J
Clin Adv Hematol Oncol; 2016 Aug; 14(8):585-7. PubMed ID: 27487101
[No Abstract] [Full Text] [Related]
5. Treatment of intermediate-stage hepatocellular carcinoma.
Finn RS
Clin Adv Hematol Oncol; 2015 Aug; 13(8):501-3. PubMed ID: 26351811
[No Abstract] [Full Text] [Related]
6. Liver transplantation for advanced hepatocellular carcinoma after downstaging with consequential lenvatinib, transcatheter arterial chemoembolization and camrelizumab.
Peng W; Wu Y; Zhang X; Li C; Shen J; Chen W; Li Q; Ma J; Yang Y; Lu W; Liu Z; Sun X; Yang J; Zhou Y; Wen T
Br J Surg; 2024 Mar; 111(3):. PubMed ID: 38447209
[No Abstract] [Full Text] [Related]
7. Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective.
Hui RW; Mak LY; Cheung TT; Lee VH; Seto WK; Yuen MF
Clin Mol Hepatol; 2023 Apr; 29(2):217-229. PubMed ID: 36577426
[TBL] [Abstract][Full Text] [Related]
8. [Resection or interventional treatment of hepatocellular carcinoma: which method for which patient?].
Lang H; Ricke J; Schlaak J
Dtsch Med Wochenschr; 2013 Sep; 138(36):1780-4. PubMed ID: 23943578
[No Abstract] [Full Text] [Related]
9. Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Tada T; Kumada T; Hiraoka A; Michitaka K; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Nakamura S; Nouso K; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y;
Oncology; 2021; 99(8):518-527. PubMed ID: 33906189
[TBL] [Abstract][Full Text] [Related]
10. Multicentric Assessment of the Hong Kong Liver Cancer Staging System in Chinese Patients Following Transarterial Chemoembolization.
Zhong BY; Ni CF; Yin GW; Chen L; Zhu HD; Guo JH; He SC; Deng G; Zhang Q; Li PC; Yu H; Teng GJ
Cardiovasc Intervent Radiol; 2018 Dec; 41(12):1867-1876. PubMed ID: 30073478
[TBL] [Abstract][Full Text] [Related]
11. [Nonsurgical management of hepatocellular carcinoma].
Merle P; Mornex F
Cancer Radiother; 2010 Oct; 14(6-7):469-73. PubMed ID: 20739209
[TBL] [Abstract][Full Text] [Related]
12. Validation of the Hong Kong liver cancer staging system in hepatocellular carcinoma patients treated with curative intent.
Wu L; Bartlett A; Plank L; McCall J
J Hepatol; 2016 Apr; 64(4):978-9. PubMed ID: 26723897
[No Abstract] [Full Text] [Related]
13. Therapeutic approaches in intermediate-stage hepatocellular carcinoma (HCC): a novel insight of adjuvant transarterial chemoembolization (TACE).
Fernández-Palanca P; Mauriz JL
Chin Clin Oncol; 2023 Apr; 12(2):11. PubMed ID: 37038055
[No Abstract] [Full Text] [Related]
14. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
Ando Y; Kawaoka T; Amioka K; Naruto K; Ogawa Y; Yoshikawa Y; Kikukawa C; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Takahashi S; Imamura M; Chayama K; Aikata H
Oncology; 2021; 99(8):507-517. PubMed ID: 33946070
[TBL] [Abstract][Full Text] [Related]
15. Liver tumors and loco-regional therapy.
Vogel W
Wien Med Wochenschr; 2013 Mar; 163(5-6):107-8. PubMed ID: 23456251
[No Abstract] [Full Text] [Related]
16. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
17. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
[No Abstract] [Full Text] [Related]
18. Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib.
Wang J; Zhao M; Han G; Han X; Shi J; Mi L; Li N; Yin X; Duan X; Hou J; Yin F
Technol Cancer Res Treat; 2023; 22():15330338231166765. PubMed ID: 37161343
[No Abstract] [Full Text] [Related]
19. Neoadjuvant combined strategy to surgery based on chemoembolization and lenvatinib in hepatocellular carcinoma.
Colón Rodríguez A; Velasco Sánchez E; Rodríguez-Bachiller L; Díaz-Zorita B; López Baena JÁ; Álvarez Luque A; Rincón Rodríguez D; Matilla Peña AM
Gastroenterol Hepatol; 2022; 45(6):490-491. PubMed ID: 34400190
[No Abstract] [Full Text] [Related]
20. Outcome of inoperable hepatocellular carcinoma patients receiving transarterial chemoembolisation: a real-life retrospective analysis in a Hong Kong regional hospital.
Yip WM; Hung HG; Lok KH; Li KF; Li KK; Szeto ML
Hong Kong Med J; 2009 Oct; 15(5):339-45. PubMed ID: 19801690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]